HIV Citation List: March 13 - March 26, 2015

PubMed Citations

1. Cell-specific RNA Aptamer against Human CCR5 Specifically Targets HIV-1 Susceptible Cells and Inhibits HIV-1 Infectivity. Zhou, J., S. Satheesan, H. Li, M.S. Weinberg, K.V. Morris, J.C. Burnett, and J.J. Rossi. Chemistry & Biology, 2015. 22(3): p. 379-390. PMID[25754473].
[PubMed]. HIV_0313-032615.

2. Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing. Wei, D.G., V. Chiang, E. Fyne, M. Balakrishnan, T. Barnes, M. Graupe, J. Hesselgesser, A. Irrinki, J.P. Murry, G. Stepan, K.M. Stray, A. Tsai, H. Yu, J. Spindler, M. Kearney, C.A. Spina, D. McMahon, J. Lalezari, D. Sloan, J. Mellors, R. Geleziunas, and T. Cihlar. Plos Pathogens, 2014. 10(4): p. e1004071. PMID[24722454].

[PubMed]. HIV_0313-032615.

3. Colorectal Mucus Binds DC-sign and Inhibits HIV-1 Trans-infection of CD4+ T-lymphocytes. Stax, M.J., E.E. Mouser, T. van Montfort, R.W. Sanders, H.J. de Vries, H.L. Dekker, C. Herrera, D. Speijer, G. Pollakis, and W.A. Paxton. Plos One, 2015. 10(3): p. e0122020. PMID[25793526].
[PubMed]. HIV_0313-032615.

4. (3Z)-3-(2-[4-(Aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one Derivatives as Dual Inhibitors of HIV-1 Reverse Transcriptase. Meleddu, R., S. Distinto, A. Corona, G. Bianco, V. Cannas, F. Esposito, A. Artese, S. Alcaro, P. Matyus, D. Bogdan, F. Cottiglia, E. Tramontano, and E. Maccioni. European Journal of Medicinal Chemistry, 2015. 93: p. 452-460. PMID[25728026].
[PubMed]. HIV_0313-032615.

5. Fused Heterocycles Bearing Bridgehead Nitrogen as Potent HIV-1 NNRTIs. Part 4: Design, Synthesis and Biological Evaluation of Novel Imidazo[1,2-a]pyrazines. Huang, B., X. Liang, C. Li, W. Chen, T. Liu, X. Li, Y. Sun, L. Fu, H. Liu, E. De Clercq, C. Pannecouque, P. Zhan, and X. Liu. European Journal of Medicinal Chemistry, 2015. 93: p. 330-337. PMID[25707013].
[PubMed]. HIV_0313-032615.

6. Herb-drug Interaction between an anti-HIV Chinese Herbal SH Formula and Atazanavir in Vitro and in Vivo. Cheng, B.H., X. Zhou, Y. Wang, J.Y. Chan, H.Q. Lin, P.M. Or, D.C. Wan, P.C. Leung, K.P. Fung, Y.F. Wang, and C.B. Lau. Journal of Ethnopharmacology, 2015. 162: p. 369-376. PMID[25614104].
[PubMed]. HIV_0313-032615.

7. Design, Synthesis of New beta-Carboline Derivatives and Their Selective anti-HIV-2 Activity. Ashok, P., S. Chander, J. Balzarini, C. Pannecouque, and S. Murugesan. Bioorganic & Medicinal Chemistry Letters, 2015. 25(6): p. 1232-1235. PMID[25682562].
[PubMed]. HIV_0313-032615.

8. Molecular Docking and Antiviral Activity of N-Substituted Benzyl/Phenyl-2-(3,4-dimethyl-5,5-dioxidopyrazolo[4,3-c][1,2]benzothiazin-2(4H)-yl)acetamides. Ahmad, M., S. Aslam, S.U. Rizvi, M. Muddassar, U.A. Ashfaq, C. Montero, O. Ollinger, M. Detorio, J.M. Gardiner, and R.F. Schinazi. Bioorganic & Medicinal Chemistry Letters, 2015. 25(6): p. 1348-1351. PMID[25701249].
[PubMed]. HIV_0313-032615.

ISI Web of Knowledge Citations

9. Bicyclic 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing Compounds Having High Potency against Raltegravir-resistant Integrase Mutants of HIV-1. Zhao, X.Z., S.J. Smith, M. Metifiot, C. Marchand, Y. Pommier, S.H. Hughes, and T.R. Burke. Abstracts of Papers of the American Chemical Society, 2014. 248: Poster #402. ISI[000349167402202].
[WOS]. HIV_0313-032615.

10. Function-oriented Development of CXCR4 Antagonists as Selective Human Immunodeficiency Virus (HIV)-1 Entry Inhibitors.Wu, C.H., C.J. Wang, C.P. Chang, Y.C. Cheng, J.S. Song, J.J. Jan, M.C. Chou, Y.Y. Ke, J. Ma, Y.C. Wong, T.C. Hsieh, Y.C. Tien, E.A. Gullen, C.F. Lo, C.Y. Cheng, Y.W. Liu, A.A. Sadani, C.H. Tsai, H.P. Hsieh, L.K. Tsou, and K.S. Shia. Journal of Medicinal Chemistry, 2015. 58(3): p. 1452-1465. ISI[000349573800034].

[WOS]. HIV_0313-032615.

11. Comparison of Antiviral Activity of lambda-Interferons against HIV Replication in Macrophages. Wang, Y., J. Li, X. Wang, Y. Zhou, T. Zhang, and W. Ho. Journal of Interferon and Cytokine Research, 2015. 35(3): p. 213-221. ISI[000350361400007].
[WOS]. HIV_0313-032615.

12. Design of Non-planar HIV Integrase Inhibitors. E.J. Velthuisen. Abstracts of Papers of the American Chemical Society, 2014. 247: Poster #186. ISI[000348457602351].
[WOS]. HIV_0313-032615.

13. Synthesis, Binding Affinity and Structure-activity Relationships of Novel, Selective and Dual Targeting CCR2 and CCR5 Receptor Antagonists. Junker, A., A.K. Kokornaczyk, A.J. Zweemer, B. Frehland, D. Scehpmann, J. Yamaguchi, K. Itami, A. Faust, S. Hermann, S. Wagner, M. Schaefers, M. Koch, C. Weiss, L.H. Heitman, K. Kopka, and B. Wunsch. Organic & Biomolecular Chemistry, 2015. 13(8): p. 2407-2422. ISI[000349669300028].
[WOS]. HIV_0313-032615.

14. Identification of Novel Small Molecule CXCR4 Inhibitors as anti-HIV Agents. Das, D., K. Maeda, Y. Hayahsi, N. Gavande, D.V. Desai, S.B. Chang, A.K. Ghosh, and H. Mitsuya. Abstracts of Papers of the American Chemical Society, 2014. 248: Poster #406. ISI[000349165104621].
[WOS]. HIV_0313-032615.

15. Toward the Synthesis of Novel Boronates as Potential HIV-1 Protease Inhibitors. Contreras, E.M., K. Sigurjonsson, M.D. Frank, N. Treich, and L. Fabry-Asztalos. Abstracts of Papers of the American Chemical Society, 2014. 247: Poster #344. ISI[000348457602496].
[WOS]. HIV_0313-032615.

Special Search Request Citations

16. TLR7 Agonist GS-9620 Activates HIV-1 in PBMCs from HIV-infected Patients on cART. Sloan, D., A. Irrinki, A. Tsai, J. Kaur, J. Lalezeari, J. Murray, and T. Cihlar. Conference on Retroviruses and Opportunistic Infections. 2015. 22: Poster #417.

[Special Search]. HIV_0313-032615.